Roche Bets on Recursion AI to Develop Novel Neuroscience Drugs, Exploring New Pathways for AI-Driven Drug R&D

TechFlow news, August 06, according to Bloomberg, Roche announced a partnership with AI drug discovery company Recursion, betting on AI technology to develop new drugs in the neuroscience field. This is one of the first attempts in the industry to adopt new AI methods to advance drug development. The background lies in the long-standing dilemma faced by the neuroscience field of unknown causes—researchers still have not fully understood the pathogenesis of diseases such as Alzheimer's disease and Parkinson's disease, leading pharmaceutical companies to repeatedly target the same set of biological targets, with most attempts ending in failure. New-generation AI companies believe that leveraging AI technology is expected to break through this bottleneck and significantly reduce the failure rate of drug trials.